SecBot SecBot

LXEO

Lexeo Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001907108 Biotech & Drug Discovery
$2.70 −0.10 (−3.57%)
Oct 26 4:00 PM ET · prev $2.80
Market cap
$237.1M
Micro cap
Consensus
Buy
94% Buy or better · 16 analysts
Median target
$20.00
+641% · range $9.00–30.00
Next earnings
Nov 9
in 13 days
1 year
−72.6%
from $9.84 · Oct 27
30 days
−14.0%
from $3.14
52-week range
$2.63–10.63
−75% from high · low Oct 14
Avg volume 20D
1.90M
Sep 29 spike 6.56M
Short interest
🔒 Subscribers only
Insider net
−$727.4K
0 buyers · 4 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 2 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 9, 2026
Strongest BULLISH Lexeo Therapeutics (LXEO) entered into a definitive agreement to acquire Mantle Therapeutics Inc. for $8.3…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $727.4K.

  • InstitutionsBULLISH

    Q2 2026: 22 added (0 new), 8 trimmed or exited.

  • AnalystsBULLISH

    15 of 16 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    31% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCADD2,833,622$13.2M
BALYASNY ASSET MANAGEMENT L.P.ADD2,412,742$11.2M
Qube Research & Technologies LtdDOUBLED1,376,222$6.4M
NORTHERN TRUST CORPADD867,391$4.0M
Aberdeen Group plcDOUBLED675,092$3.1M
BNP PARIBAS FINANCIAL MARKETSADD388,398$1.8M
FMR LLCDOUBLED141,146$657.0K
RAYMOND JAMES FINANCIAL INCDOUBLED117,388$546.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 94% rate it Buy or better
Strong Buy8Buy7Hold1Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +641%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 23, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Jun 25, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
May 11, 2026Chardan Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$727.4K
sold · 4 insiders
DateInsiderTypeValue
Sep 24, 2026
Bhalla Narinder Pal
Chief Medical Officer
AWARD54,750 sh
Sep 24, 2026
Otero Jose Manuel
Chief Operating Officer
AWARD54,750 sh
Sep 24, 2026
Tamayo Louis Edward
Chief Financial Officer
AWARD54,750 sh
Sep 24, 2026
Townsend Richard Nolan
Chief Executive Officer
AWARD145,500 sh
Sep 14, 2026
Otero Jose Manuel
Chief Operating Officer
AWARD$5.6K
Sep 14, 2026
Townsend Richard Nolan
Chief Executive Officer
AWARD$6.1K
Sep 14, 2026
Bhalla Narinder Pal
Chief Medical Officer
AWARD$9.7K
Aug 18, 2026
Townsend Richard Nolan
Chief Executive Officer
SELL$16.6K

Earnings setup

Estimates
Nov 9
reports in 13 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 Other
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in P
Oct 13, 2026 SEC
JPMorgan Chase & Co. disclosed a 5.5% passive stake in Lexeo Therapeutics via a Schedule 13G filed October 13, 2026…
SC 13G — Impact 3/10
Sep 24, 2026 Insider
Bhalla Narinder Pal was granted 54,750 shares
Chief Medical Officer
Sep 24, 2026 Insider
Otero Jose Manuel was granted 54,750 shares
Chief Operating Officer
Sep 24, 2026 Insider
Tamayo Louis Edward was granted 54,750 shares
Chief Financial Officer
Sep 22, 2026 SEC
Lexeo Therapeutics (LXEO) entered into a definitive agreement to acquire Mantle Therapeutics Inc. for $8.3 million in…
8-K — Impact 6/10
Aug 12, 2026 SEC
Lexeo Therapeutics reported Q2 2026 financial results with a net loss of $0.30 per share, slightly better than the…
8-K — Impact 7/10
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — ADD
2,833,622 shares ($13.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
LXEO Q3 2026 Earnings Scheduled — 2026-11-09
Recent
Oct 19, 2026
Press release
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM...
Oct 1, 2026
Press release
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
Sep 23, 2026
Press release
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Sep 9, 2026
Trial readout
T-90d Trial Readout: Gene Therapy for ACM Due to a PKP2 Pathogenic Vari (Phase 2)
Trial: Gene Therapy for ACM Due to a PKP2 Pathogenic Variant Sponsor: Lexeo Therapeutics Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING Conditions…
Sep 2, 2026
Trial readout
T-90d Trial Readout: Gene Therapy for ACM Due to a PKP2 Pathogenic Vari (Phase 2)
Trial: Gene Therapy for ACM Due to a PKP2 Pathogenic Variant Sponsor: Lexeo Therapeutics Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING Conditions…

SecBot reports

11 filings · 2 press releases · 7 bullish · 0 bearish · 4 neutral
All LXEO filing & press-release reports (13)